High-Dose Quadrivalent Flu Shot Increases Production Capability

Sanofi announced the U.S. Food and Drug Administration (FDA) Center for Biologics Evaluation and Research had granted approval to Sanofi Pasteur for an additional influenza manufacturing facility located in Swiftwater, PA.

The newly completed facility further expands production and distribution of Sanofi's Fluzone® High-Dose Quadrivalent for the upcoming 2021-2022 influenza season in the USA.

"We are experiencing fast-growing demand for our vaccine in the U.S. and globally, given the 10 years of data demonstrating protection from flu and its related complications," said Elaine O'Hara, Head of North America Commercial Operations for Sanofi Pasteur, in a press statement.

"Our new facility will complement our existing capacities to produce enough high-dose vaccine for all people 65 and older in as many countries as possible this flu season and beyond, supporting the needs of healthcare providers and patients."

Fluzone Quadrivalent contains the 2 strains of influenza A and B identified for the current flu season. The vaccine is given to people 6 months of age and older. And Fluzone High-Dose is a vaccine given to people 65 years of age and older that also contains 4 killed flu virus strains.

With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.